Related Experiment Video

Updated: Aug 9, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cetuximab in the treatment of colorectal cancer

Fortunato Ciardiello1, Ferdinando De Vita, Michele Orditura

  • 1Seconda Università degli Studi di Napoli, Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica Sperimentale F Magrassi e A Lanzara, Via S Pansini 5, 80131- Napoli, Italy. fortunato.ciardiello@unina2.it

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

Cetuximab targets epidermal growth factor receptor (EGFR) and shows efficacy in metastatic colorectal cancer. Further trials are investigating its combination with standard chemotherapy for improved treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in colorectal cancer development and resistance.
  • Therapeutic targeting of EGFR is a key strategy in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Cetuximab in metastatic colorectal cancer.
  • To explore Cetuximab's potential in combination with standard chemotherapy regimens.

Main Methods:

  • Clinical trials investigating Cetuximab efficacy.
  • Combination therapy studies with irinotecan and FOLFOX regimens.

Main Results:

  • Cetuximab demonstrates efficacy in metastatic colorectal cancer patients.
  • Cetuximab is well-tolerated and does not increase chemotherapy toxicity.

Conclusions:

  • Cetuximab is a viable therapeutic option for metastatic colorectal cancer.
  • Combination of Cetuximab with chemotherapy warrants further investigation in Phase III trials for chemotherapy-naive patients.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...